MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$1,460K
Free Cash flow
-$14,180K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of secu...
    • Stock-based compensation
    • Amortization of operating lease ...
    • Others
Negative Cash Flow Breakdown
    • Purchases of securities
    • Operating lease liabilities
    • Prepaid expenses and other asset...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-14,469
-14,697
-13,781
-13,574
Stock-based compensation
1,158
1,362
1,471
1,496
Amortization of operating lease right-of-use assets
1,012
1,142
1,183
1,193
Depreciation
-
-
1,753
-
In-process research and development
-
-
0
-
Depreciation
272
-1,014
-
426
Amortization (accretion) of premiums (discounts) on securities, net
-12
68
134
306
Prepaid expenses and other assets
598
355
-395
11
Accounts payable
-304
200
2
-20
Accrued expenses and other liabilities
248
128
-703
942
Operating lease liabilities
-1,057
-1,146
-1,213
-1,180
Net cash used in operating activities
-13,726
-13,100
-12,375
-11,034
Proceeds from maturities of securities
29,910
25,805
34,750
28,363
Purchases of securities
17,434
11,062
33,719
27,493
Purchases of property and equipment
454
510
244
418
Cash paid in connection with asset acquisition
-
-
0
-
Net cash provided by investing activities
12,022
14,233
787
452
Proceeds from exercise of stock options
102
1,105
32
0
Proceeds from issuance of common stock under employee stock purchase plan
142
-
69
0
Net cash provided by financing activities
244
1,105
101
0
Net increase in cash, cash equivalents and restricted cash
-1,460
2,238
-11,487
-10,582
Cash, cash equivalents and restricted cash at beginning of period
15,628
13,390
24,877
28,648
Cash, cash equivalents and restricted cash at end of period
14,168
15,628
13,390
24,877
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof securities$29,910K (-34.81%↓ Y/Y)Proceeds from issuance ofcommon stock under...$142K (63.22%↑ Y/Y)Proceeds from exercise ofstock options$102K (292.31%↑ Y/Y)Net cash provided byinvesting activities$12,022K (-64.63%↓ Y/Y)Net cash provided byfinancing activities$244K (115.93%↑ Y/Y)Canceled cashflow$17,888K Net increase incash, cash...-$1,460K (-121.44%↓ Y/Y)Canceled cashflow$12,266K Stock-based compensation$1,158K (-70.13%↓ Y/Y)Amortization of operatinglease right-of-use...$1,012K (-56.68%↓ Y/Y)Depreciation$272K (-70.50%↓ Y/Y)Accrued expenses andother liabilities$248K (-36.41%↓ Y/Y)Amortization (accretion) ofpremiums (discounts) on...-$12K (-101.22%↓ Y/Y)Purchases of securities$17,434K (54.58%↑ Y/Y)Purchases of property andequipment$454K (-26.18%↓ Y/Y)Net cash used inoperating activities-$13,726K (49.70%↑ Y/Y)Canceled cashflow$2,702K Net loss-$14,469K (54.28%↑ Y/Y)Operating leaseliabilities-$1,057K (53.94%↑ Y/Y)Prepaid expenses andother assets$598K (473.75%↑ Y/Y)Accounts payable-$304K (-496.08%↓ Y/Y)

Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology, Inc. (NAUT)